CASI Pharmaceuticals - CASI Company Long-Term Liabilities

casipharmaceuticals.com - graphic logo of issuer CASI

CASI Pharmaceuticals (CASI) is a reputable intermediary providing access to advanced blood cancer treatments for residents of China. The business relies on strict compliance with NMPA regulations, which creates a significant barrier to entry for new players. The licensing model for Western drugs minimizes R&D risks, and the debt load ratio is 0.00. This chart of current share prices on GURU.Markets confirms the holding's market positions.

CASI (CASI Pharmaceuticals) Company Long-Term Debt history from 07/04/2022 to 03/14/2026

Summary analytical data breakdowns for CASI Pharmaceuticals, Inc. (CASI)

- price and consensus price forecast:
Share Price CASI Pharmaceuticals Inc.|CASI - Analyst Consensus Forecast
- market capitalization data:
Market Valuation CASI Pharmaceuticals|CASI - Enterprise Value
- book capitalization data:
Net Asset Value per Share CASI Pharmaceuticals|CASI - Company Book Value|Market Value to Book Value casipharmaceuticals.com|CASI - Cumulative Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio CASI Pharmaceuticals|CASI - Long-Term Debt to Capital|Short-Term Debt to Equity CASI Pharmaceuticals Inc.|CASI - Company Debts|Debt to Book Capitalization Ratio CASI Pharmaceuticals|CASI - Company Long-Term Debt|Short-Term Debt CASI Pharmaceuticals
Analysis of all company metrics:CASI Pharmaceuticals (CASI)
Original product of CASI Pharmaceuticals Inc.

To select high-quality assets, investors analyze the liability structure to assess capital resilience against long-term risks. This metric captures the total amount of loans with maturities exceeding one year, reflecting the balance between financial security and expansion rates, which is critical for CASI Pharmaceuticals (CASI) when financing costly clinical trials for oncology drugs and developing its R&D pipeline, based on the company's current level of long-term debt.

Direct competitors

Company Long-Term Indebtedness tgtherapeutics.com TGTX|ACLX: Company Long-Term Debts|IRON - Company Long-Term Liabilities|Company Long-Term Debts SNDX|KURA (Kura) - Long-Term Debt|ADCT - Company Long-Term Debt|Company Long-Term Loans and Borrowings Foghorn (FHTX)|Vor Biopharma (VOR) - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings nkartatx.com (NKTX)|Company Long-Term Debts Coeptis Therapeutics, Inc. COEP|Actinium Corp - Company Long-Term Debt|ESLA - Company Long-Term Debt|MRKR: Company Long-Term Debt|Company Long-Term Debt INAB|ERNA (Eterna Therapeutics Inc.) - Long-Term Debt|Company Long-Term Debt GTBP (GT Biopharma Corp)|Long-Term Debt Aptose|Company Long-Term Debts Bio-Path Holdings BPTH|Company Long-Term Indebtedness meipharma.com (MEIP)|Vincerx Pharma - Company Long-Term Debts